

# Inez H G B Ramakers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4668263/publications.pdf>

Version: 2024-02-01

65  
papers

2,718  
citations

304602

22  
h-index

197736

49  
g-index

70  
all docs

70  
docs citations

70  
times ranked

4540  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
2	Anxiety as a Predictor for Cognitive Decline and Dementia: A Systematic Review and Meta-Analysis. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 823-842.	0.6	239
3	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.4	179
4	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
5	Variability of CSF Alzheimer's Disease Biomarkers: Implications for Clinical Practice. <i>PLoS ONE</i> , 2014, 9, e100784.	1.1	72
6	Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 846-854.	1.7	69
7	Characteristics of help-seeking behaviour in subjects with subjective memory complaints at a memory clinic: a case-control study. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 190-196.	1.3	63
8	Alzheimer's disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms. <i>Molecular Psychiatry</i> , 2021, 26, 897-906.	4.1	58
9	The Dutch Parelinoer Institute - Neurodegenerative diseases; methods, design and baseline results. <i>BMC Neurology</i> , 2014, 14, 254.	0.8	57
10	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 101.	3.0	43
11	Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2021, 31, 102712.	1.4	42
12	The Influence of Co-Morbidity and Frailty on the Clinical Manifestation of Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 501-509.	1.2	34
13	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1025-1034.	1.2	33
14	The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 735-744.	0.6	33
15	Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 389-397.	1.2	30
16	Development of memory clinics in the Netherlands over the last 20 years. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1267-1274.	1.3	30
17	Development of memory clinics in the Netherlands: 1998 to 2009. <i>Aging and Mental Health</i> , 2011, 15, 34-39.	1.5	29
18	Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer's disease: A systematic literature review. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 346-359.	2.9	29

#	ARTICLE	IF	CITATIONS
19	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 309-320.	1.2	27
20	Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration. <i>Scientific Reports</i> , 2021, 11, 22675.	1.6	27
21	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. <i>Alzheimer's and Dementia</i> , 2022, 18, 29-42.	0.4	24
22	DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. <i>Epigenomics</i> , 2015, 7, 533-537.	1.0	23
23	Apolipoprotein E and affective symptoms in mild cognitive impairment and Alzheimer's disease dementia: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 96, 302-315.	2.9	23
24	The clinical course and interrelations of dementia related symptoms. <i>International Psychogeriatrics</i> , 2018, 30, 859-866.	0.6	22
25	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
26	The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 679-689.	1.2	20
27	Alzheimer's disease biomarkers as predictors of trajectories of depression and apathy in cognitively normal individuals, mild cognitive impairment and Alzheimer's disease dementia. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 224-234.	1.3	20
28	Neuropsychological assessment and diagnostic disclosure at a memory clinic: A qualitative study of the experiences of patients and their family members. <i>Clinical Neuropsychologist</i> , 2021, 35, 1398-1414.	1.5	19
29	A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands. <i>BMC Neurology</i> , 2016, 16, 242.	0.8	17
30	Association Between Proxy- or Self-Reported Cognitive Decline and Cognitive Performance in Memory Clinic Visitors. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 1225-1239.	1.2	17
31	A survey on the prevalence of apathy in elderly people referred to specialized memory centers. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1369-1377.	1.3	16
32	Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. <i>Diabetologia</i> , 2021, 64, 2445-2457.	2.9	13
33	A Scoping Review of Communicating Neuropsychological Test Results to Patients and Family Members. <i>Neuropsychology Review</i> , 2022, 32, 294-315.	2.5	12
34	Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 107, 1-10.	1.5	12
35	The Predictive Value of Memory Strategies for Alzheimer's Disease in Subjects with Mild Cognitive Impairment. <i>Archives of Clinical Neuropsychology</i> , 2010, 25, 71-77.	0.3	10
36	Cognitive and functional progression of dementia in two longitudinal studies. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1623-1632.	1.3	6

#	ARTICLE	IF	CITATIONS
37	Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 256-264.	1.2	6
38	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. <i>Translational Psychiatry</i> , 2021, 11, 451.	2.4	6
39	The Role of Vascular Risk Factors in Biomarker-Based AT(N) Groups: A German-Dutch Memory Clinic Study. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 185-195.	1.2	6
40	Feasibility Study of an Internet-Based Platform for Tele-Neuropsychological Assessment of Elderly in Remote Areas. <i>Diagnostics</i> , 2022, 12, 925.	1.3	6
41	Remote cognitive assessment of older adults in rural areas by telemedicine and automatic speech and video analysis: protocol for a cross-over feasibility study. <i>BMJ Open</i> , 2021, 11, e047083.	0.8	5
42	Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer's disease scale: development and results from a mapping study. <i>Quality of Life Research</i> , 2021, 30, 867-879.	1.5	4
43	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2023, 19, 807-820.	0.4	4
44	An Exploratory Study of the Development and Pilot Testing of an Interactive Visual Tool of Neuropsychological Test Results in Memory Clinics. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1157-1170.	1.2	3
45	A comparison of two approaches for modeling dementia progression in a changing patient context. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	3
46	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
47	CSF proteomic profiling of mild cognitive impairment individuals with suspected non-Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2020, 16, e047247.	0.4	1
48	P1-182: THE EFFECT OF PSYCHOLOGICAL DISTRESS AND PERSONALITY TRAITS ON COGNITIVE TEST PERFORMANCES AND THE RISK OF DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT. , 2014, 10, P366-P366.		0
49	O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF). , 2015, 11, P130-P130.		0
50	O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test. , 2015, 11, P272-P272.		0
51	O2-02-06: Slow gait speed and low grip strength are related to worse attention and mental speed in patients with subjective cognitive decline and mild cognitive impairment. , 2015, 11, P177-P177.		0
52	F4-02-02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors. , 2015, 11, P260-P261.		0
53	P1-366: Subjective Versus Objective Cognitive Decline in Memory Clinic Visitors. , 2016, 12, P571-P571.		0
54	P2-270: INCREASED CSF AMYLOID $\beta$ 1-38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P780.	0.4	0

#	ARTICLE	IF	CITATIONS
55	P3â€232: THE ASSOCIATION BETWEEN BLOODâ€BRAINâ€BARRIER DYSFUNCTION AND CSF Pâ€TAU IS MEDIATED BY BETAâ€AMYLOID IN THE PRESENCE OF ELEVATED ILâ€6. Alzheimer's and Dementia, 2018, 14, P1160.	0.4	0
56	P1â€332: APOLIPOPROTEIN E GENOTYPE AND AFFECTIVE NEUROPSYCHIATRIC SYMPTOMS: A SYSTEMATIC REVIEW AND METAâ€ANALYSIS. Alzheimer's and Dementia, 2018, 14, P420.	0.4	0
57	CSF AÎ²42, Pâ€tau and noradrenaline metabolite MHPG levels are synergistically related to cortical thickness in a memory clinic population. Alzheimer's and Dementia, 2020, 16, e037481.	0.4	0
58	Vascular and neurodegenerative imaging markers are associated with increased interstitial fluid diffusion in memory clinic patients. Alzheimer's and Dementia, 2020, 16, e039700.	0.4	0
59	Correlations of plasma kynurenines with CSF levels, and their relation to markers of Alzheimerâ€™s disease pathology, diagnostic phases and cognitive performance. Alzheimer's and Dementia, 2020, 16, e041474.	0.4	0
60	Validation of a telemedicine tool for patient monitoring in clinical dementia trials. Alzheimer's and Dementia, 2020, 16, e047345.	0.4	0
61	Remote cognitive assessment of older adults in rural areas by telemedicine and automatic speech and video analysis: protocol for a cross-over feasibility study. BMJ Open, 2021, 11, e047083.	0.8	0
62	Screening for neuropsychological assessment in the diagnostics of Neurocognitive disorder. International Psychogeriatrics, 2022, , 1-7.	0.6	0
63	The prevalence of vascular risk factors in different AD biomarker profiles. Alzheimer's and Dementia, 2021, 17, .	0.4	0
64	Automated speech analysis for detection of cognitive and emotional changes. Alzheimer's and Dementia, 2021, 17, .	0.4	0
65	Interstitial fluid as a proxy of glymphatic dysfunction in patients with cognitive impairment: The necessity of threeâ€directional intravoxel incoherent motion. Alzheimer's and Dementia, 2021, 17, .	0.4	0